EBQ:RE-LY: Difference between revisions

Revision as of 21:35, 31 October 2014

incomplete Journal Club Article

Connolly SJ, et al. "Dabigatran versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 2009. 361(12):1139-51.
PubMed Full text PDF

Clinical Question

Is dabigatran (brand name Pradaxa) safe for use in patients with atrial fibrillation when compared to warfarin in terms of stroke and bleeding risks.

Conclusion

In comparison to warfarin in patients with atrial fibrillation, dabigatran given at a dose of 110 mg demonstrated similar stroke and lower bleeding rates. At 150 mg, dabigatran use was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.

Major Points

Design

Randomized, prospective, blinded, multinational study
Patients recruited from 951 clinical sites in 44 countries
3 treatment groups: Warfarin, Dabigatrin 110 mg BID, Dabigatrin 150 mg BID
Dabigatrin groups were blinded, Warfarin was not
Followed for 2 years

Inclusion Criteria

Exclusion Criteria

Interventions

Outcome

Primary Outcomes

Secondary Outcomes

Subgroup analysis

Criticisms

Funding

Sources

Authors:

@@ Line 20: / Line 20: @@
 In comparison to warfarin in patients with atrial fibrillation, dabigatran given at a dose of 110 mg demonstrated similar stroke and lower bleeding rates.  At  150 mg, dabigatran use was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage.
 ==Major Points==
+==Design==
+*Randomized, prospective, blinded, multinational study
+*Patients recruited from 951 clinical sites in 44 countries
+*3 treatment groups: Warfarin, Dabigatrin 110 mg BID, Dabigatrin 150 mg BID
+*Dabigatrin groups were blinded, Warfarin was not
+*Followed for 2 years
 ==Inclusion Criteria==